# TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

> **NCT03952091** · PHASE3 · COMPLETED · sponsor: **TJ Biopharma Co., Ltd.** · enrollment: 289 (actual)

## Conditions studied

- Multiple Myeloma in Relapse
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** TJ202, Lenalidomide and Dexamethasone
- **DRUG:** Lenalidomide and Dexamethasone

## Key facts

- **NCT ID:** NCT03952091
- **Lead sponsor:** TJ Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-27
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 289 (ACTUAL)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03952091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03952091, "TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03952091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*